Dysregulation of the EGF-EGFR signaling pathway has been implicated in several pathological conditions. For instance, overexpression of EGFR is commonly observed in various cancers, including lung, breast, and colorectal cancers. This overexpression leads to uncontrolled cell proliferation and survival, contributing to tumor growth and metastasis. Inhibitors of EGFR are, therefore, used as targeted therapies in cancer treatment.
